Sunshine Biopharma (SBFM) Cash from Operations (2010 - 2026)

Sunshine Biopharma's Cash from Operations history runs 17 years deep, the most recent figure standing at 2072100.0 for Q1 2026.

• Quarterly Cash from Operations fell 22.25% year-over-year to 2072100.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5708171.0 (up 48.27% YoY) and the FY2025 annual result came in at 5331073.0, up 57.44% from the prior year.
• Cash from Operations was 2072100.0 for Q1 2026 at Sunshine Biopharma, down from 1616006.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 457289.0 in Q3 2023 and bottomed at 4577784.0 in Q2 2024.
• A 5-year average of 1997142.41 and a median of 1695002.0 in 2025 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 619.81% — and 2025, when it jumped 71.77%.
• Sunshine Biopharma's Cash from Operations stood at 2246612.0 in 2022, then declined by 19.72% to 2689676.0 in 2023, then fell by 26.6% to 3405260.0 in 2024, then soared by 52.54% to 1616006.0 in 2025, then decreased by 28.22% to 2072100.0 in 2026.
• Business Quant data shows SBFM's Cash from Operations at 2072100.0 in Q1 2026, 1616006.0 in Q4 2025, and 727800.0 in Q3 2025.